OBJECTIVES - To investigate the clinical and microbiological features in the patients with community-acquired
(CA-ABP), as well as factors that affect fluoroquinolone resistance.
A retrospective analysis was performed of 209 patients hospitalized for antibiotic treatment of CA-ABP.
We investigated patient age,
body mass index, underlying diseases, recurrence, prostate-related factors and results of urine culture examination and antibiotic sensitivity tests.
RESULTS - Pain While Urinating Seventeen patients (8.1%) had fluoroquinolone-resistant bacterial colonies. When we divided the subjects into groups according to the fluoroquinolone resistance, the group with resistant bacteria was significantly older, had larger prostates and had greater Frequent Urination residual urine volumes. Bacteria were identified in 127 of 209 patients (60.8%), and the most commonly cultured included Escherichia
coli (43.5%). The sensitivity of the cultured bacteria to fluoroquinolones was high compared to Painful ejaculation trimethoprim/sulfamethoxazole and gentamicin, Prostatitis Symptoms but similar to cefotaxime. The bacteria were more sensitive to amikacin and imipenem than to fluoroquinolone. The multivariate
analysis revealed that prostate volume ≥40 ml (p = 0.024) and residual urine volume >100 ml (p = 0.004) Difficulty Urinating were independent predictive factors for fluoroquinolone resistance.
chronic Pelvic Pain Syndrome - Fluoroquinolone monotherapy might be an effective treatment in CA-ABP. However, combination antibiotic therapy is Burning While Urinating recommended in cases with prostate volume ≥40 ml or BPH residual urine volume >100 ml,
because fluoroquinolone resistance can occur.